LEADERSHIP
FOR THE
LONG VIEW

THE KALA MANAGEMENT TEAM

THE BOARD OF DIRECTORS

THE KALA MANAGEMENT TEAM

Divider

THE BOARD OF DIRECTORS

MARK IWICKI

Chairman and
Chief Executive Officer

Mr. Iwicki has more than 25 years of experience leading all aspects of R&D and commercialization in the biopharmaceutical industry. He is the Chairman, President and CEO of Kala Pharmaceuticals and was previously the CEO of Civitas Therapeutics which was acquired by Acorda Therapeutics. ...see more Prior to Civitas, Mr. Iwicki served as the President and Chief Executive Officer of Blend Therapeutics and President and Chief Executive Officer of Sunovion Pharmaceuticals. He was President and Chief Operating Officer at Sepracor, which was acquired in 2009. During his tenure at Novartis he was Business Unit Head and managed the Cardiovascular, Diabetes, Arthritis, Bone, Gastrointestinal, HRT, Infectious Diseases and Urology therapeutic areas. Previously, Mr. Iwicki held management positions at Merck and Astra Merck. He also currently serves on the boards of Aimmune Therapeutics, Inc., Merus N.V., Pulmatrix Inc. and Akero Therapeutics, Inc., all publicly-traded companies, and Nimbus Therapeutics, Inc. and Oxeia Biopharmaceuticals, Inc., which are privately-held biotech companies. Mr. Iwicki holds a B.S. from Ball State University and an M.B.A. from Loyola University. ...see less

TODD BAZEMORE

Chief Operating Officer

Mr. Bazemore is a biopharmaceutical executive with 25 years of experience spanning from ultra-rare orphan diseases to large primary care conditions. ...see more Prior to joining Kala Pharmaceuticals, Todd served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (USA), Inc. since September 2016, where he was instrumental in building the U.S. operations to support the company’s regulatory and commercial strategy. Prior to joining Santhera U.S., Todd served as Executive Vice President and Chief Commercial Officer of Dyax Corp., where he was responsible for global commercial strategy and oversight of all commercial functions. Dyax was acquired by Shire Plc in January of 2016. Prior to joining Dyax, Todd was at Sunovion Pharmaceuticals, Inc. (previously Sepracor Inc., prior to its acquisition by Sumitomo Dainippon Pharma Co., Ltd), where he served in several roles of increasing responsibility including Vice President, Managed Markets, Vice President of Sales, and Vice President of Respiratory Business Unit. He began his career in sales at MURO Pharmaceuticals. Todd has a Bachelor’s of Science in Health from the University of Massachusetts at Lowell. ...see less

KIM BRAZZELL, PhD

Chief Medical Officer

Dr. Brazzell has served as our Chief Medical Officer since February 2013. He has also served as a Principal of Acuity Advisors, LLC, an ophthalmic consulting company, from January 2014 to July 2018. ...see more Dr. Brazzell served as Chief Medical Officer of Mimetogen Pharmaceuticals, Inc., a clinical stage biotechnology company, from January 2012 until December 2015. Dr. Brazzell also held several executive positions at Inspire Pharmaceuticals, Inc., or Inspire, a specialty pharmaceutical company focusing on ophthalmic products, including Executive Vice President of Medical and Scientific Affairs from 2010 to 2011, Executive Vice President and Head of Ophthalmology Business from 2009 to 2010, and Senior Vice President of Ophthalmic Research and Development from 2004 to 2008. Prior to joining Inspire, Dr. Brazzell served as Global Head of Clinical R&D and Senior Vice President, U.S. R&D, of Novartis Ophthalmics AG from 2000 to 2004. Dr. Brazzell also served as Vice President, R&D at Ciba Vision Ophthalmics, Inc. and as Associate Director, R&D, at Alcon Laboratories, Inc. Dr. Brazzell received a B.S. in Pharmacy and a PhD in Pharmaceutical Sciences from the University of Kentucky. ...see less

HONGMING CHEN, ScD

Chief Scientific Officer

Dr. Chen has served as our Chief Scientific Officer since October 2014. Prior to that, Dr. Chen served as our Executive Vice President of Research from October 2013 to October 2014 and our Vice President of Research from January 2010 to October 2013. ...see more Prior to joining us, Dr. Chen served as Director of Formulation Development at TransForm Pharmaceuticals Inc., or TransForm, from 2000 to January 2010. Before joining TransForm, Dr. Chen conducted vaccine delivery research and development at AstraZeneca plc from 1997 to 2000, and at Merck & Co., Inc. from 1996 to 1997. Dr. Chen is a member of the National Academy of Engineering, the College of Fellows of the American Institute for Medical and Biological Engineering and the College of Fellows of the Controlled Release Society. Dr. Chen received a B.S. in Chemical Engineering from The University of Texas at Austin in 1992 and both an M.S. and a ScD. in Chemical Engineering from the Massachusetts Institute of Technology. ...see less

MARY REUMUTH, CPA

Chief Financial Officer

Ms. Reumuth has served as our Chief Financial Officer since July 2017, Senior Vice President, Finance from February 2017 to July 2017, our Vice President, Finance from December 2014 to February 2017, our Senior Director, Finance from February 2014 to December 2014, as our Corporate Controller from February 2014 to July 2017 and Treasurer since February 2014. ...see more Prior to joining us, Ms. Reumuth acted as an independent financial consultant from November 2012 to January 2014 and, prior to that, served as Corporate Controller for Enobia Pharma Corp., or Enobia, a global biopharmaceutical company acquired by Alexion Pharmaceuticals, Inc., from May 2011 to June 2012. Prior to Enobia, Ms. Reumuth served as Director of Finance at Verenium Corporation, or Verenium, a biotechnology company, from December 2007 to March 2011. From 2001 to 2007, Ms. Reumuth held a variety of finance and accounting positions at Genzyme Corporation, or Genzyme, (now a Sanofi Company), and ILEX Oncology, Inc., or ILEX (acquired by Genzyme). Prior to ILEX, Ms. Reumuth was an auditor at Ernst & Young LLP. Ms. Reumuth earned her Bachelor’s degree in Business Administration from Texas A&M University—Corpus Christi, and is a Certified Public Accountant. ...see less

ERIC L. TRACHTENBERG

General Counsel and Chief Compliance Officer

Mr. Trachtenberg has been practicing law for over 20 years, most of which has been spent in the life sciences industry. He has served as our General Counsel and Corporate Secretary since April 2018 and as our Chief Compliance Officer since June 2018. ...see more Previously, he served as General Counsel, Chief Compliance Officer and Corporate Secretary of Aralez Pharmaceuticals Inc., from February 2016 to March 2018. Prior to that, he served in similar capacities for Pozen Inc., Aralez’s predecessor, from June 2015 to February 2016. Mr. Trachtenberg also formerly served as Deputy General Counsel at Auxilium Pharmaceuticals, Inc. from May 2012 through its acquisition by Endo Pharmaceuticals in February 2015. Prior to Auxilium, he was Vice President, General Counsel and Corporate Secretary of Enobia Pharma, Inc. from April 2011 through its acquisition by Alexion Pharmaceuticals in April 2012. Prior to that, Mr. Trachtenberg served as Vice President and Associate General Counsel of Sepracor Inc. (now known as Sunovion Pharmaceuticals Inc.) commencing in May 2007 and remained in that position following the acquisition of Sepracor Inc. by Dainippon Sumitomo Pharma through April 2011. Mr. Trachtenberg also held a Senior Counsel position at Kos Pharmaceuticals, Inc. from July 2005 to April 2007 before its acquisition by Abbott. Mr. Trachtenberg began his career at Blank Rome LLP. He holds a Juris Doctorate and Master of Business Administration from Temple University and a Bachelor of Science in Management from Tulane University. ...see less

VINCENT KOSEWSKI

Senior Vice President of Manufacturing
and Supply Chain Management

Mr. Kosewski has served as our Senior Vice President of Manufacturing and Supply Chain Management since July 2017. Prior to joining us, Mr. Kosewski served as Vice President, Supply Chain Operations at Sunovion Pharmaceuticals Inc. from October 2010 to June 2017. ...see more He was also Vice President and General Manager at Sunovion’s manufacturing subsidiary, Sepracor Canada Ltd., from 2010 to 2015. Prior to joining Sunovion, Mr. Kosewski held several positions at Sepracor, Inc., including Vice President, Supply Chain Operations from 2007 to 2010. Mr. Kosewski began his pharmaceutical career at Astra USA, Inc., holding positions in quality assurance, manufacturing, procurement and business development. Mr. Kosewski holds a B.S. in Chemistry from Fairfield University and an M.B.A.from Bryant University. ...see less

Steven Zhang, MD, PhD

Senior Vice President of Medical Affairs

Dr. Zhang has over 15 years of experience in pharmaceutical medical affairs with more than 10 years in the ophthalmic industry. ...see more Dr. Zhang joined Kala in August 2018 as Vice President of Medical Affairs. Prior to joining Kala, Dr. Zhang was the Head of US Ophthalmic Medical Affairs and Global Ophthalmic Franchise Medical Lead at Shire Plc. Dr. Zhang began his industry career at Abbott Laboratories Inc., holding positions in clinical and medical sciences at Abbott and Bausch+Lomb Inc. Dr. Zhang has a MD degree, a Master’s degree in pharmacology and a PhD degree in biophysics with training and research at the California Institute of Technology (Caltech). ...see less

Mark Iwicki

Chairman and Chief Executive Officer

Mr. Iwicki has more than 25 years of experience leading all aspects of R&D and commercialization in the biopharmaceutical industry. He is the Chairman, President and CEO of Kala Pharmaceuticals and was previously the CEO of Civitas Therapeutics which was acquired by Acorda Therapeutics. ...see more Prior to Civitas, Mr. Iwicki served as the President and Chief Executive Officer of Blend Therapeutics and President and Chief Executive Officer of Sunovion Pharmaceuticals. He was President and Chief Operating Officer at Sepracor, which was acquired in 2009. During his tenure at Novartis he was Business Unit Head and managed the Cardiovascular, Diabetes, Arthritis, Bone, Gastrointestinal, HRT, Infectious Diseases and Urology therapeutic areas. Previously, Mr. Iwicki held management positions at Merck and Astra Merck. He also currently serves on the boards of Aimmune Therapeutics, Inc., Merus N.V., Pulmatrix Inc. and Akero Therapeutics, Inc., all publicly-traded companies, and Nimbus Therapeutics, Inc. and Oxeia Biopharmaceuticals, Inc., which are privately-held biotech companies. Mr. Iwicki holds a B.S. from Ball State University and an M.B.A. from Loyola University. ...see less

Divider

Howard B. Rosen

Board Member

Mr. Rosen has served as a member of our board of directors since January 2014. Since 2008, Mr. Rosen has served as a consultant to several companies in the biotechnology industry. He has also served as a lecturer at Stanford University in Chemical Engineering since 2009 and in Management since 2011. ...see more Mr. Rosen served as Chief Executive Officer of AcelRx Pharmaceuticals, Inc., or AcelRx, a public specialty pharmaceutical company developing products for pain relief, from April 2016 to March 2017, and Interim Chief Executive Officer from April 2015 to March 2016. Mr. Rosen also served as Interim President and Chief Executive Officer of Pearl Therapeutics, Inc. from June 2010 to March 2011. From 2004 to 2008, Mr. Rosen was Vice President of Commercial Strategy at Gilead Sciences, Inc., a biopharmaceutical company. From 2003 until 2004, Mr. Rosen was President of ALZA Corporation, a pharmaceutical and medical systems company that merged in 2001 with Johnson & Johnson, a global healthcare company. Prior to that, from 1994 until 2003, Mr. Rosen held various positions at ALZA Corporation. Mr. Rosen is a member of the board of directors of AcelRx, a public pharmaceutical company, and also served on the board of directors of Alcobra, Ltd., a public pharmaceutical company, until November 2017. Mr. Rosen is also currently a member of the board of directors of private companies, including Hammerton, Inc., Metera Pharmaceuticals, Inc. and Entrega, Inc., and was a member of the board of directors of PaxVax, Inc. from 2007 to 2015. Mr. Rosen holds a B.S. in Chemical Engineering from Stanford University, an M.S. in Chemical Engineering from the Massachusetts Institute of Technology and an M.B.A. from the Stanford Graduate School of Business. ...see less

Divider

Gregory Grunberg, MD, MBA

Board Member

Managing Director, Longitude Capital

Dr. Grunberg has served as a member of our board of directors since April 2016. Dr. Grunberg has been a Managing Director at Longitude Capital Management Co., LLC, a venture capital firm and a current 5% stockholder, or Longitude, since 2012 and has focused on drug development and medical technology solutions. ...see more Prior to joining Longitude, Dr. Grunberg was a Principal at Rho Ventures, a venture capital firm from 2007 to 2012, and an Engagement Manager at McKinsey & Company, a management consulting firm from 2004 to 2007. Dr. Grunberg is a board-certified physician in Internal Medicine and completed his residency at Cornell’s New York Presbyterian Hospital. He has maintained a limited clinical practice in Internal Medicine and affiliations with University of California, San Francisco and Kaiser Permanente. Dr. Grunberg currently serves on the boards of 89bio, Inc. and WelbeHealth LLC. He is also a board observer at Sydnexis, Inc. He previously served on the board of California Cryobank (acquired by GI Partners). While at Rho Ventures he served on the board of AqueSys (acquired by Allergan) and was a board observer at both SARCode Bioscience (acquired by Shire) and PHT (acquired by ERT). Dr. Grunberg holds an M.D. and an M.B.A from Duke University where he was a Fuqua Scholar and an A.B. in Economics and English from Amherst College. ...see less

Divider

Rajeev Shah

Board Member

Managing Director & Portfolio Manager, RA Capital

Mr. Shah has served as a member of our board of directors since July 2015. Since 2004, Mr. Shah has been a managing partner at RA Capital Management, L.P., a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics and current 5% beneficial stockholder. ...see more Mr. Shah is currently a member of the board of directors of Solid Biosciences, Inc., Eidos Therapeutics, Inc., Satsuma Pharmaceuticals, Inc., and Black Diamond Therapeutics, Inc., all publicly-traded biopharmaceuticals companies. Mr. Shah was previously a member of the board of directors of KalVista Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from June 2015 through April 2018 and Ra Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from July 2015 through April 2020. Mr. Shah holds a B.A. in Chemistry from Cornell University. ...see less

Divider

Robert Paull

Board Member

Co-Founder and Venture Partner, Lux Capital

Mr. Paull has served as a member of our board of directors since July 2009. Mr. Paull was a co-founder of, and since 2014 has been a Venture Partner at, Lux Capital Management, or Lux Capital, where he focuses on healthcare ventures. ...see more In addition, Mr. Paull served as our founding Chief Executive Officer, President and Treasurer from July 2009 to June 2012. Mr. Paull also served as founding Chief Executive Officer of Genocea Biosciences Inc., a vaccine discovery and development company, from August 2006 to February 2009, and was the co-founder of Lux Research, Inc., an emerging technology market research and consulting firm, which was founded in January 2004. Since January 2018, Mr. Paull has been Chief Executive Officer of Mahana Therapeutics, Inc., a digital therapeutics company. Mr. Paull holds a B.S. in Architecture from the University of Virginia. ...see less

Divider

Andrew I. Koven

Board Member

Mr. Koven has served as a member of our board of directors since September 2017 and as our Lead Independent Director since December 2018. Mr. Koven was, until his retirement in January 2019, the President and Chief Business Officer of Aralez Pharmaceuticals Inc., or Aralez, a public specialty pharmaceutical company, and served in that role with the company’s predecessor, Pozen Inc., commencing in June 2015. ...see more Prior to joining Pozen, Mr. Koven served as Executive Vice President, Chief Administrative Officer and General Counsel of Auxilium Pharmaceuticals Inc., a public specialty biopharmaceutical company, from February 2012 until January 2015, when it was acquired by Endo International plc. Mr. Koven served as President and Chief Administrative Officer and a member of the board of directors of Neurologix, Inc., a company focused on the development of multiple innovative gene therapy development programs, from September 2011 to November 2011. Before Neurologix, Mr. Koven served as Executive Vice President and Chief Administrative and Legal Officer of Inspire Pharmaceuticals, Inc., a public specialty pharmaceutical company, from July 2010 until May 2011 when it was acquired by Merck & Co., Inc. Previously, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Sepracor Inc. (now Sunovion), a public specialty pharmaceutical company, from March 2007 until February 2010 when it was acquired by Dainippon Sumitomo Pharma Co., Ltd. Prior to joining Sepracor, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Kos Pharmaceuticals, Inc., a public specialty pharmaceutical company, from August 2003 until its acquisition by Abbott Laboratories (now AbbVie) in December 2006. Mr. Koven began his career in the pharmaceutical industry first as an Assistant General Counsel and then as Associate General Counsel at Warner-Lambert Company from 1993 to 2000, followed by his role as Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003. From 1986 to 1992 he was a corporate associate at Cahill, Gordon & Reindel in New York. From 1992 to 1993 he served as Counsel, Corporate and Investment Division, at The Equitable Life Assurance Society of the U.S. Mr. Koven holds a Master of Laws (LL.M.) Degree from Columbia University School of Law and a Bachelor of Laws (LL.B.) Degree and Bachelor of Arts Degree in Political Science from Dalhousie University. ...see less

Divider

Gregory Perry

Board Member

Mr. Perry has served as a member of our board of directors since February 2018. Mr. Perry has served as Chief Financial Officer for Finch Therapeutics Group, Inc., a private therapeutics company focused on the microbiome, since June 2018. Previously, he served as Chief Financial and Administrative Officer of Novelion Therapeutics Inc., or Novelion, a public biopharmaceutical company, from November 2016 to December 2017. ...see more Prior to this, Mr. Perry was Chief Financial Officer of Aegerion Pharmaceuticals Inc, a public biopharmaceutical company, from July 2015 until its merger with Novelion in November 2016. Prior to that, he served as Chief Financial and Business Officer of Eleven Biotherapeutics, Inc., a public company, from January 2014 to June 2015. Before joining Eleven Biotherapeutics, Mr. Perry served as the Interim Chief Financial Officer of InVivo Therapeutics, a public biotechnology company, from September 2013 to December 2013, and prior to that he served as the Senior Vice President and Chief Financial Officer of ImmunoGen, Inc., a public biotechnology company, from 2009 until he was promoted in 2011 to Executive Vice President and Chief Financial Officer, a role he held until 2013. Before that, he was the Chief Financial Officer of Elixir Pharmaceuticals. Mr. Perry previously was Senior Vice President and Chief Financial Officer of Transkaryotic Therapies. He has also held various financial leadership roles within PerkinElmer Inc., Domantis Ltd., Honeywell and General Electric. Since May 2016, Mr. Perry has served on the board of directors of Merus N.V., a public clinical-stage immuno-oncology company, including as Chair of its Audit Committee. From December 2011 to February 2016, Mr. Perry served on the board of directors of Ocata Therapeutics, a public biotechnology company, including as Chair of its Audit Committee and a member of its Compensation Committee, until it was acquired by Astellas Pharma Inc. Mr. Perry received a B.A. in Economics and Political Science from Amherst College. ...see less

Please review our Privacy Statement. This website uses cookies. By using our website without changing your cookie settings you agree to our use of cookies as described in our Privacy Statement.